Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome, whose pathogenesis begins with the accumulation of liver fat and is followed by the development of necro-inflammation and fibrosis. Recent evidence indicates that adipocytokines, polypeptides secreted by the adispose tissue, might play an important role in the pathogeneic process and progression of NAFLD. In this review, we explore the role of leptin, and in part of other adipocytokines, in the interference with hepatic injury associated with fatty infiltration, in the modulation of steatosis and fibrosis, in both experimental models of the disease and in the clinical practice. We also discuss the potential use of leptin as non-invasive marker for differentiating simple fatty liver from NAFLD, and the possible novel therapeutic strategies aimed at interfering with the leptin axis to dampen chronic liver inflammation and NAFLD.

Leptin: the prototypic adipocytokine and its role in NAFLD / Procaccini, C; Galgani, M; De Rosa, V; Carbone, F; La Rocca, C; Ranucci, G; Iorio, R; Matarese, Giuseppe. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - STAMPA. - 16:17(2010), pp. 1902-1912. [10.2174/138161210791208884]

Leptin: the prototypic adipocytokine and its role in NAFLD.

Galgani M;Iorio R;MATARESE, GIUSEPPE
2010

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome, whose pathogenesis begins with the accumulation of liver fat and is followed by the development of necro-inflammation and fibrosis. Recent evidence indicates that adipocytokines, polypeptides secreted by the adispose tissue, might play an important role in the pathogeneic process and progression of NAFLD. In this review, we explore the role of leptin, and in part of other adipocytokines, in the interference with hepatic injury associated with fatty infiltration, in the modulation of steatosis and fibrosis, in both experimental models of the disease and in the clinical practice. We also discuss the potential use of leptin as non-invasive marker for differentiating simple fatty liver from NAFLD, and the possible novel therapeutic strategies aimed at interfering with the leptin axis to dampen chronic liver inflammation and NAFLD.
2010
Leptin: the prototypic adipocytokine and its role in NAFLD / Procaccini, C; Galgani, M; De Rosa, V; Carbone, F; La Rocca, C; Ranucci, G; Iorio, R; Matarese, Giuseppe. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - STAMPA. - 16:17(2010), pp. 1902-1912. [10.2174/138161210791208884]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/621977
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 49
social impact